Avalo Therapeutics (AVTX) Enterprise Value (2016 - 2025)
Avalo Therapeutics (AVTX) has disclosed Enterprise Value for 12 consecutive years, with -$84.7 million as the latest value for Q3 2025.
- For the quarter ending Q3 2025, Enterprise Value fell 206592.68% year-over-year to -$84.7 million, compared with a TTM value of -$84.7 million through Sep 2025, down 206592.68%, and an annual FY2024 reading of -$19000.0, down 1800.0% over the prior year.
- Enterprise Value was -$84.7 million for Q3 2025 at Avalo Therapeutics, down from -$71.0 million in the prior quarter.
- Across five years, Enterprise Value topped out at -$1000.0 in Q3 2023 and bottomed at -$84.7 million in Q3 2025.
- Average Enterprise Value over 5 years is -$9.6 million, with a median of -$46000.0 recorded in 2021.
- The sharpest move saw Enterprise Value skyrocketed 99.98% in 2024, then plummeted 206592.68% in 2025.
- Year by year, Enterprise Value stood at -$51000.0 in 2021, then skyrocketed by 70.59% to -$15000.0 in 2022, then surged by 93.33% to -$1000.0 in 2023, then crashed by 1800.0% to -$19000.0 in 2024, then tumbled by 445921.05% to -$84.7 million in 2025.
- Business Quant data shows Enterprise Value for AVTX at -$84.7 million in Q3 2025, -$71.0 million in Q2 2025, and -$62000.0 in Q1 2025.